This is a routine scientific disclosure with no near-term stock catalyst. Monitor for the actual poster data at IHW (July 12) and any subsequent partnership or funding news, but historical performance on this ticker shows neutral reads have been weak to negative. The core value driver remains Evaxion's cash runway and clinical progress on its oncology pipeline, not this preclinical CMV data.
Price Chart
Executive Summary
Evaxion announced a poster presentation at the International Herpesvirus Workshop 2026 for its preclinical CMV vaccine candidate EVX-V1. The data will guide final antigen selection for this next-generation candidate, but this is an early-stage, non-clinical event with no financial terms, regulatory action, or near-term value inflection — simply a routine scientific conference disclosure for a preclinical program.
Key Facts
- Poster presentation of new preclinical data for EVX-V1 at IHW 2026 in Montreal on July 12, 2026.
- EVX-V1 is a multi-component CMV vaccine candidate combining AI-discovered antigens with AI-optimized gB antigen.
- The data will guide final antigen selection for the vaccine candidate — no clinical timeline or regulatory milestone announced.
- No CMV vaccine has been approved to date; Evaxion remains at the preclinical stage for this program.
- Evaxion is a clinical-stage TechBio with ~$26M market cap and no approved products; cash-certainty is the primary concern.
Financial Impact
No financial figures provided — preclinical data presentation with no funding, deal value, or revenue impact.
Risk Factors
- Historical pattern on EVAX shows neutral-labeled reports have led to negative T+20 outcomes (~ -10% avg), suggesting negative drift that may continue regardless of this news.
- CMV vaccine development is notoriously difficult — no approved vaccine exists despite decades of effort.
- Preclinical data does not guarantee progression to clinical trials; Evaxion may need additional capital to advance EVX-V1.
- Evaxion's ~$26M market cap and lack of revenue create binary financing risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3320532 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.56%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.88%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.13%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.13%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.56%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.89%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.89%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.39%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.39%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access